Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Long-term Debt?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Long-term Debt is 
$9.6B (1Y +0.42% )

ALXN Stock Price & Long-term Debt

Long-term Debt for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Long-term Debt

chevron_right 2021 $2.4B +6048x
( +38.1% / year avg)
chevron_left 1995 $400.0K
vertical_align_top Peak $11.3B +56504x
vertical_align_bottom Bottom $200.0K
arrow_drop_up # Up Years 15 15 of 27
years up.
arrow_drop_down # Down Years 10
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.01x the rate relative to it's long-term debt over the same period.
  • If ALXN grows it's stock at the same rate as it's long-term debt (+38.1%/year) , it's stock price will grow +2,523% and hit $2743.13 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 15 years (0%) it's long-term debt were also up.
  • ALXN Historical Long-term Debt Table
    in $ million
    Year Long-term Debt YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $2,419 -74.5% - -
    4/1/2020 $9,483 -3.4% - -
    4/1/2019 $9,816 -6.5% - -
    4/1/2018 $10,497 -7.1% - -
    4/1/2017 $11,301 16.9% - -
    4/1/2016 $9,665 15.2% - -
    4/1/2015 $8,392 4970.9% - -
    4/1/2014 $165 -55.0% - -
    4/1/2013 $368 -49.3% - -
    4/1/2012 $726 268.0% - -
    4/1/2011 $197 102.7% - -
    4/1/2010 $97 -79.8% - -
    4/1/2009 $482 -38.2% - -
    4/1/2008 $781 8.2% - -
    4/1/2007 $722 20.3% - -
    4/1/2006 $600 0.0% - -
    4/1/2005 $600 25.0% - -
    4/1/2004 $480 -3.7% - -
    4/1/2003 $498 0.5% - -
    4/1/2002 $495 0.0% - -
    4/1/2001 $495 31.8% - -
    4/1/2000 $376 2625.7% - -
    4/1/1999 $13 820.0% - -
    4/1/1998 $1 650.0% - -
    4/1/1997 $0 -71.4% - -
    4/1/1996 $0 75.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Long Term Debt (LTD) is any amount of outstanding debt a company holds that has a maturity of 12 months or longer. It is classified as a non-current liability on the company's balance sheet. These statements are key to both financial modeling and accounting.

    For more detailed definitions, please see Investopedia.